Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;16(1):11-8.
doi: 10.1159/000109754. Epub 2007 Dec 5.

Biomarkers for early detection of Alzheimer pathology

C M Clark  1 , C Davatzikos, A Borthakur, A Newberg, S Leight, V M-Y Lee, J Q Trojanowski
Affiliations
Review

Biomarkers for early detection of Alzheimer pathology

C M Clark et al. Neurosignals. 2008.

Abstract

The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T(1)rho to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hippocampus volume in 3 diagnostic groups.
Fig. 2
Fig. 2
Volumetric measurements using high-dimensional template warping (HAMMETR technique).
Fig. 3
Fig. 3
Gray matter MRI T1ρ in AD and control subjects.
Fig. 4
Fig. 4. d
Improvement in biomarker performance with data fusion.
See this image and copyright information in PMC

References

    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer’s Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–2117. - PMC - PubMed
    1. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295–303. - PubMed
    1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122. - PubMed
    1. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 2004;1:213–225. - PMC - PubMed
    1. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003;2:605–613. - PubMed

Publication types